You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Second Pivotal Phase III Study of Gilead's Darusentan for Resistant Hypertension Misses Primary Endpoints
FDA Advisory Committee Supports Use of Aztreonam for Inhalation Solution for Patients With Cystic Fibrosis
Gilead Sciences to Present at the NASDAQ OMX 23rd Investor Program
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead Sciences to Present at the Lazard Capital Markets 6TH Annual Healthcare Conference on Tuesday, November 17
Gilead Sciences to Present at the 18th Annual Credit Suisse Healthcare Conference on Wednesday, November 11
Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
Gilead Announces Long-Term Data from Two Pivotal Phase III Studies Evaluating Viread(R) For Chronic Hepatitis B
Gilead Sciences to Present at the Oppenheimer 20th Annual Healthcare Conference on Tuesday, November 3
Gilead's Aztreonam for Inhalation Solution to be Reviewed by FDA Anti-Infective Drugs Advisory Committee on December 10, 2009
Gilead Sciences Announces Record Third Quarter 2009 Financial Results
Gilead Sciences to Release Third Quarter 2009 Financial Results on Tuesday, October 20, 2009
European Commission Grants Conditional Marketing Authorization to Cayston(R) (Aztreonam Lysine) for the Treatment of Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis
Gilead Sciences to Present at the UBS Global Life Sciences Conference on Monday, September 21
Pivotal Data Demonstrating Efficacy of Darusentan in Treating Resistant Hypertension Published in The Lancet
Gilead Sciences to Present at Three Upcoming Investor Conferences
Gilead Sciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on Wednesday, September 9
Gilead Sciences' Executive Vice President Establishes Rule 10b5-1 Stock Trading Plan
Gilead Sciences Receives Subpoena from U.S. Department of Health & Human Services Regarding Ranexa(R)
Gilead Announces Senior Management Promotion
Kevin E. Lofton Joins Gilead Sciences' Board of Directors
Gilead Sciences Announces Record Second Quarter 2009 Financial Results
Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring
Gilead Sciences Announces Agreement With Tibotec Pharmaceuticals to Develop and Commercialize New Fixed-Dose Combination of Truvada(R) and TMC278
Gilead Sciences to Release Second Quarter 2009 Financial Results on Tuesday, July 21, 2009
European CHMP Adopts Positive Opinion for Aztreonam Lysine
Gilead Sciences to Present at the Piper Jaffray 4th Annual Europe Conference on Wednesday, June 24
Gilead Sciences to Present at Two Upcoming Investor Conferences
Gilead Sciences' Marketing Authorisation Application for Regadenoson Validated by European Medicines Agency
Gilead Sciences Announces Changes to Cardiovascular R&D Organization Leadership
New Data for Gilead Sciences' Ambrisentan Show Clinical Improvements in a Diverse Pulmonary Hypertension (PH) Population
Gilead Sciences to Present at the Deutsche Bank 34th Annual Healthcare Conference on Tuesday, May 19
Gilead Sciences Files Second Patent Infringement Lawsuit Against Teva Pharmaceuticals
Gilead Palo Alto, Inc. Announces Tender Offer for Convertible Notes
Gilead Sciences' Phase III Darusentan Data Show Significant Blood Pressure Reductions in Resistant Hypertension Patients
Gilead Sciences Announces Record First Quarter 2009 Financial Results
Gilead Sciences Completes Acquisition of CV Therapeutics
Gilead Initiates Phase II Clinical Trial of Integrase-Based, Single-Tablet, Once-Daily Regimen for the Treatment of HIV
Gilead Sciences Successfully Completes Tender Offer for Shares of CV Therapeutics With Over 88 Percent of Shares Tendered
Gilead Sciences to Release First Quarter 2009 Financial Results on Tuesday, April 21, 2009
Phase III Data for Gilead Sciences' Darusentan Accepted as Late-Breaker Presentation at ASH 2009
Gilead Sciences Announces Notification of ANDA Filing for Atripla(R)
Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints
Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period
Gilead Initiates Phase II Clinical Trial of Cicletanine for the Treatment of Pulmonary Arterial Hypertension
European CHMP Adopts Negative Opinion on Aztreonam Lysine
Department of Justice Declines to Intervene in False Claims Act Lawsuits Against Gilead Sciences
Gilead Sciences Agrees to Acquire CV Therapeutics for $20.00 Per Share
Gilead Sciences to Present at the Cowen and Company 29th Annual Healthcare Conference on Monday, March 16
Gilead Sciences to Present at the Barclays Capital Global Healthcare Conference on Tuesday, March 10
Gilead Receives Response From U.S. FDA on Company's Request for Formal Dispute Resolution for Aztreonam for Inhalation Solution
Gilead Announces Data Demonstrating Pharmacokinetic Boosting Activity of GS 9350
Gilead Sciences to Present at the 11th Annual BIO CEO Investor Conference on Tuesday, February 10
Gilead Completes Acquisition of Building and Associated Land from EFI
Gilead Outlines R&D Priorities for 2009
Gilead Sciences Announces Record Fourth Quarter and Full Year 2008 Financial Results
Gilead Sciences to Release Fourth Quarter and Year End 2008 Financial Results on Tuesday, January 27, 2009
Gilead Sciences to Present at the 27th Annual JPMorgan Healthcare Conference on Monday, January 12
2012 Interactive Annual Report